Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

被引：29
|
作者：
Yee, Andrew J. [1 ]
Raje, Noopur S. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA
来源：
CLINICAL INTERVENTIONS IN AGING | 2012年 / 7卷
关键词：
denosumab; zoledronic acid; bone loss; breast cancer; prostate cancer; ADJUVANT ENDOCRINE THERAPY; ANDROGEN-DEPRIVATION THERAPY; PLUS ZOLEDRONIC ACID; BREAST-CANCER; POSTMENOPAUSAL WOMEN; PROSTATE-CANCER; DOUBLE-BLIND; OSTEOCLAST DIFFERENTIATION; PREMENOPAUSAL WOMEN; MULTIPLE-MYELOMA;
D O I：
10.2147/CIA.S14566
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer.
引用
收藏
页码：331 / 338
页数：8
相关论文
共 50 条
  • [41] BONE LOSS AND NEW FRACTURES WITH DENOSUMAB TREATMENT
    Sanguesa, C.
    Casafont-Sole, I.
    Nack, A.
    Holgado Perez, S.
    Martinez-Morillo, M.
    Aparicio Rovira, M.
    Prior-Espanol, A.
    Aparicio Espinar, M.
    Riveros, A.
    Mateo, L.
    Olive, A.
    Gifre, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1754 - 1755
  • [42] Effect of risedronate on bone loss at discontinuation of denosumab
    Laroche, Michel
    Couture, Guillaume
    Ruyssen-Witrand, Adeline
    Constantin, Arnaud
    Degboe, Yannick
    [J]. BONE REPORTS, 2020, 13
  • [43] Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection
    Otto, Sven
    Baumann, Sebastian
    Ehrenfeld, Michael
    Pautke, Christoph
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2013, 41 (07) : 694 - 698
  • [44] Denosumab in the management of Aneurysmal bone cyst
    Maximen, Julien
    Robin, Francois
    Tronchot, Alexandre
    Rossetti, Adrien
    Ropars, Mickael
    Guggenbuhl, Pascal
    [J]. JOINT BONE SPINE, 2022, 89 (01)
  • [45] Effects of RANK-Ligand Antibody (Denosumab) Treatment on Bone Turnover Markers in a Girl With Juvenile Paget's Disease
    Grasemann, Corinna
    Schuendeln, Michael M.
    Hoevel, Matthias
    Schweiger, Bernd
    Bergmann, Christoph
    Herrmann, Ralf
    Wieczorek, Dagmar
    Zabel, Bernhard
    Wieland, Regina
    Hauffa, Berthold P.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08): : 3121 - 3126
  • [46] Denosumab-A Powerful RANKL Inhibitor to Stop Lytic Metastases and Other Bone Loss Actions by Osteoclasts
    Kopper, Laszlo
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (04) : 743 - 747
  • [47] Efficacy of denosumab on bone mineral density in postmenopausal women with low bone mass and patients with breast cancer on adjuvant aromatase inhibitor (AI) therapy
    Bone, H. G.
    Ellis, G.
    Yuen, C. K.
    Kendler, D. L.
    Fan, M.
    Wang, H.
    Kim, D.
    Liu, Y.
    Dansey, R.
    Martin, J. San
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S38 - S38
  • [48] Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
    Lipton, Allan
    Smith, Matthew R.
    Ellis, Georgiana K.
    Goessl, Carsten
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 287 - 303
  • [49] Cancer Treatment-Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review
    Dabkara, Deepak
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (03) : 240 - 246
  • [50] The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases
    Lechner, Breanne
    DeAngelis, Carlo
    Jamal, Noreen
    Emmenegger, Urban
    Pulenzas, Natalie
    Giotis, Angie
    Sheehan, Parker
    Tsao, May
    Bedard, Gillian
    Chow, Edward
    [J]. SUPPORTIVE CARE IN CANCER, 2014, 22 (07) : 1765 - 1771
12345